Transducin

Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments

Retrieved on: 
Tuesday, February 20, 2024
NCI, Neoplasm, WNT, FDA, Drug development, Overalls, Metastasis, National Cancer Institute, Death, Survival rate, Prevalence, Safety, Prognosis, Therapy, Plantar fibromatosis, Patient, Clinical trial, Transducin, Trial of the century, HCC, Cancer, Pharmaceutical industry

Unfortunately, key members of this pathway (including beta-catenin) have either been resistant to conventional drug development or plagued with off-target toxicities.

Key Points: 
  • Unfortunately, key members of this pathway (including beta-catenin) have either been resistant to conventional drug development or plagued with off-target toxicities.
  • Extensive pre-clinical study results across multiple tumor types suggest that TBL1 is a downstream target that is necessary for Wnt/beta-catenin-activated oncogenesis.
  • Tegavivint has demonstrated safety, clinical and pharmacodynamic activity in a Phase 1 clinical study of patients with desmoid tumors.
  • For more information about this Phase 1b/2a clinical trial of tegavivint in patients with advanced HCC, please visit www.ClinicalTrials.gov using the identifier NCT05797805.

Desmoid Tumors Drug Pipeline Research Report 2023: Comprehensive Insights About 12+ Companies and 12+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 16, 2023
Health, Pharmaceutical, Plantar fibromatosis, NDA, Aggressive fibromatosis, Acquisition, Research, Safety, Toxicity, Therapy, Disease, Clinical trial, Patient, FDA, Transducin, Mergers and acquisitions, New Drug Application, Nirogacestat, Orphan, Discovery, News, Medical imaging, Pharmaceutical industry

This pipeline report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Desmoid Tumors pipeline landscape.

Key Points: 
  • This pipeline report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Desmoid Tumors pipeline landscape.
  • This report provides an in-depth analysis of the Desmoid Tumors pipeline, covering both clinical and nonclinical stage products.
  • The report offers comprehensive insights into the current scenario and growth prospects within the Desmoid Tumors indication.
  • Companies and academic institutions are actively working to assess challenges and identify opportunities that could impact the research and development of therapies for Desmoid Tumors.

Iterion Therapeutics Announces Results from Preclinical Study of Tegavivint in Beta-Catenin Mutant Hepatocellular Carcinoma to be Presented at the 34th EORTC-NCI-AACR Symposium 2022

Retrieved on: 
Tuesday, October 18, 2022
CET, Therapy, Population, Acute myeloid leukemia, AML, Squamous cell carcinoma, ENA, Neoplasm, Patient, American Association for Cancer Research, Molecule, Hepatocellular carcinoma, Research, HCC, Sarcoma, Metastasis, Cancer Prevention and Research Institute of Texas, C57BL/6J, GEMM, Research institute, SCI, Treatment, Mouse, National Cancer Institute, AACR, NSCLC, European Organisation for Research and Treatment of Cancer, Cancer research, American Association, Toxicity, CEO, EORTC, Transducin, Cancer prevention, Osteosarcoma, Lymphoma, Literature, Homeostasis, Death, Cell membrane, NCI, Large-cell lung carcinoma, Pharmaceutical industry, Medical imaging, Cancer

HOUSTON, Oct. 18, 2022 /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, announced that results from a preclinical murine study of tegavivint in beta-catenin activated hepatocellular carcinoma (HCC) will be featured in a poster presentation and discussion session at the 34th European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI), and American Association for Cancer Research (AACR) Symposium (ENA 2022). ENA 2022 is being held October 26-28, 2022, in Barcelona, Spain.

Key Points: 
  • Increased expression of beta-catenin and TBL1 are associated with metastasis and poor prognosis in a broad range of tumor types, including HCC.
  • Up to 50% of HCC patients have tumors driven by activating beta-catenin and canonical Wnt pathway mutations.
  • Additionally, in mice with established tumors, tegavivint treatment increased CD3+ T-lymphocyte tumor infiltration, with prominent increases in intratumoral CD8+ T-cells.
  • Iterion is currently advancing multiple clinical programs investigating tegavivint in cancer indications where nuclear beta-catenin overexpression is a known factor.

Iterion Therapeutics Announces Results from Phase 1 Dose Escalation Study of Tegavivint in Desmoid Tumors to be Presented at the 2022 ASCO Annual Meeting

Retrieved on: 
Wednesday, June 1, 2022
Transducin, MD Anderson Cancer Center, Adult, Large-cell lung carcinoma, Cell membrane, Research, Society, The James Cancer Hospital, Doctor of Philosophy, AACR, Toxicity, WNT, Plasma, Metastasis, CEO, ASCO, AML, Research institute, Toxic leukoencephalopathy, MTD, Plantar fibromatosis, Sarcoma, Therapy, Patient, Acute myeloid leukemia, Lymphoma, Cancer Prevention and Research Institute of Texas, CDT, Poster, Children's Oncology Group, Index (publishing), NSCLC, Safety, Cancer prevention, Pharmaceutical industry

HOUSTON , June 1, 2022 /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced that results from a Phase 1 study of tegavivint in patients with desmoid tumors will be featured in a poster presentation and discussion session at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO 2022). ASCO 2022 is being held June 3-7, 2022, in Chicago, Illinois.

Key Points: 
  • Increased expression of beta-catenin and TBL1 are associated with metastasis and poor prognosis in a broad range of tumor types.
  • The poster details results from the Phase 1 trial in adult patients with progressive, unresectable desmoid tumors.
  • The primary objectives of the study were to evaluate safety and to determine the maximum tolerated dose (MTD), the recommended Phase 2 dose (RP2D), and exploratory efficacy.
  • These cancer indications, like desmoid tumors, are associated with nuclear beta-catenin overexpression, which has historically been considered undruggable.

Iterion Therapeutics Announces Presentation of Three Posters Involving Research into Tegavivint at the AACR 2022 Annual Meeting

Retrieved on: 
Friday, April 8, 2022
Drug development, Therapy, Headache, Plasma, Large-cell lung carcinoma, WHO, Transducin, AML, Texas Children's Hospital, Growth, RECIST, Adult, MTD, ALT, Infrared spectroscopy correlation table, AACR, Research, Doctor of Philosophy, Hospital, CDT, Metastasis, Neoplasm, Stomatitis, Trae Elston, American Association, CEO, Poster, Osteosarcoma, OS, MD, Index (publishing), Association, Safety, DLT, National Postdoctoral Association, Plantar fibromatosis, Cell membrane, Hypophosphatemia, Disease, Toxicity, Pharmaceutical industry, Medical imaging, Patient

HOUSTON, April 8, 2022 /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced that three posters involving research into tegavivint will be presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting, including initial results from a Phase 1 study of tegavivint in patients with desmoid sarcomas. AACR 2022 is being held April 8-13, 2022, in New Orleans.

Key Points: 
  • AACR 2022 is being held April 8-13, 2022, in New Orleans.
  • The poster details results from the dose-escalation portion of a Phase 1 trial of tegavivint in adult patients with progressive, unresectable desmoid sarcoma.
  • Research demonstrating potent anti-tumor activity in a broad range of pre-clinical models indicate that tegavivint has the potential for clinical utility in multiple cancer types.
  • Iterion is the recipient of an up to$15.9 millionProduct Development Award from the Cancer Prevention and Research Institute ofTexas (CPRIT).For more information on Iterion, please visit https://iteriontherapeutics.com .